RxDoctor Payments Data

Christine Trinh, DO

Family Medicine · San Jose, CANPI 1053974147

Payments from drug & device makers

$3,216in general payments, 2019–2025

Across 137 payments — averaging $23.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$545
  • Novo Nordisk$387
  • Amgen$364
  • Gilead$272
  • GSK$270
  • AstraZeneca$245
  • plus $1K from 18 others

What the payments were for

  • Food & beverage$3,216100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,216 in reported general payments places this provider in the 85th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$20,001
Medicare patients
39
Services billed
267

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin41$60,348
RybelsusSemaglutide36$53,460
FarxigaDapagliflozin Propanediol44$38,930
OzempicSemaglutide36$36,222
GemtesaVibegron31$25,401
Repatha SureclickEvolocumab22$11,740
KerendiaFinerenone17$11,086
VascepaIcosapent Ethyl13$8,461
Atorvastatin Calcium242$2,202
Rosuvastatin Calcium94$1,817
Rifampin33$1,734
Losartan Potassium171$1,588
Fluticasone Propionate114$1,359
Omega-3 Acid Ethyl Esters14$1,329
Celecoxib58$1,265

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$387$89,68272 claims
Boehringer IngelheimJardiance$22$60,34841 claims
AstraZenecaFarxiga$245$38,93044 claims
Sumitomo Pharma America, Inc.Gemtesa$177$25,40131 claims
BayerKerendia$122$11,08617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,533 family medicine providers in California.

Other family medicine in San Jose

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →